[ad_1]
NEW YORK: Pfizer and its partner BioNTech plan to give volunteers who received a placebo in their COVID-19 vaccine trial the option to receive a first dose of the vaccine before March 1, 2021, while they remain in the study.
The trial vaccine transition option allows all participants 16 years of age or older the option to find out if they received the placebo, “and participants who learn they received the placebo have the option of receiving the investigational vaccine while they stay in the studio. ” the companies said on their website for trial participants.
The US Food and Drug Administration and a panel of its outside advisers have raised concerns about Pfizer’s “unmasking” plan, saying it could make it difficult to collect the safety and efficacy data needed to gain full approval. of the vaccine by the FDA.
READ: WHO lists Pfizer-BioNTech COVID-19 vaccine for emergency use
READ: How does AstraZeneca’s COVID-19 vaccine compare to Pfizer-BioNTech?
Trial participants who received the placebo will have two doses of the investigational vaccine reserved for them within the study, the companies said on the website.
“The study physician will follow the latest guidelines from the US Centers for Disease Control and Prevention and their local health authorities to offer the vaccine transition option to participants on a prioritized basis,” said the Business.
CHECK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments
Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram
